



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2014

Rs in Lakhs

Sl. No.	Particulars	Three months	Three months	Three months	Year Ended
		Ended	Ended	Ended	31.3.2014
		30.6.2014	31.03.2014	30.06.2013	31.3.2014
		(Un- Audited)	(Audited)	(Un-Audited)	(Audited)
1	Income from Operations :				
	(a) Net Sales / Income from Operations	950.25	938.53	760.13	3,395.21
	(b) Other Operating Income	4.34	4.36	1.30	12.25
	Total Income From operations (net)	954.59	942.89	761.43	3,407.46
2	Expenses :				
	a) Operating Expenses	36.25	37.97	21.25	121.69
	b) Purchases of stock in trade	740.36	757.46	625.07	2,760.83
	c) Changes in inventories of finished goods Work-in-progress and stock-in-goods	(2.45)	(3.88)	(1.20)	(9.70)
	d) Employee benefits expense	13.23	13.86	9.24	47.40
	e) Depreciation and amortisation expense	67.04	32.47	25.25	114.25
	f) Power And Fuel	12.18	12.14	12.36	50.00
	g) Freight and Forwarding Expenses	4.21	4.81	3.24	16.79
	h) Other Expenses	12.35	22.74	21.25	85.30
	Total Expenses (a+b+c+d+e+f+g+h)	883.17	877.57	716.46	3,186.56
	Profit/(Loss) from operations before other Income and				
	Finance costs (1-2)	71.42	65.32	44.98	220.90
3	Other Income	-	-	-	-
5	Profit/(Loss) From ordinary activities before finance Cost (3+/-)4)	71.42	65.32	44.98	220.90
6	Finance cost	57.07	52.92	35.63	178.05
7	Profit/(Loss) from ordinary activities before Tax (5+/-)6)	14.35	12.40	9.35	42.85
8	Tax expenses				
	(a) Current Tax	2.65	-	-	-
	(b) Deferred Tax	-	2.97	2.00	8.97
	Total (a+b)	2.65	2.97	2.00	8.97
9	Net profit/(loss) for the period (7+/-)8)	11.69	9.43	7.35	33.88
10	Minority interest	-	-	-	-
11	Net Profit/(Loss) after Taxes and minority interest (9+/-)10)	11.69	9.43	7.35	33.88
12	Paid up Equity Share Capital (Face value of Rs.10/- per share)	724.38	724.38	724.38	724.38
13	Reserves excluding Revaluation Reserve as per balance sheet at year end	-	-	-	537.68
14	Earnings Per Share(of Rs.10/- each) (not annualised)				
	a) Basic	0.16	0.13	0.10	0.47
	b) diluted	0.16	0.13	0.10	0.47



Part II
Select Information for the Quarter Ended 30/06/2014

Sl. No.	Particulars	Three months Ended	Three months Ended	Three months Ended	Year Ended
		30.6.2014	31.03.2014	30.06.2013	31.3.2014
1	Public Shareholding				
	- Number of shares	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	60.79%	60.79%	60.79%	60.79%
2	Promoter and Promoter group Shareholding(ExcludingGDRS)				
	a) Pledged/Encumbered				
	- Number of Shares	--	--	--	--
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group	--	--	--	--
	- Percentage of shares (As a % of total share Capital of the Company	--	--	--	--
	b) Non-Encumbered				
	- Number of Shares	2840500	2840500	2840500	2840500
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (As a % of total share Capital of the Company	39.21%	39.21%	39.21%	39.21%
B	Particulars	The Quarter ended 30/06/2014			
	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	NIL	NIL		
	Received during the quarter	NIL	NIL		
	Disposed of during the quarter	NIL	NIL		
	Remaining unresolved at the end of the quarter	NIL	NIL		

NOTES:

- The above results for the quarter ended 30.06.2014 were reviewed by the Audit Committee at its meeting held on 13.08.2014 and approved by the Board of Directors in the meeting held on 13.08.2014. The statutory auditors of the Company have conducted limited review of these results.
- The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment viz., pharmaceuticals
- Previous period's figures have been reclassified / regrouped / rearranged wherever necessary to confirm to current quarter presentation. The figures for the quarter ended March 2014 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the previous quarter.

For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Managing director

Place: Hyderabad
Date: 13.08.2014